At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
TAK-228drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating TAK-228 for Renal Cell Carcinoma. Completed, enrolled 39 participants across 8 sites.
Detailed Summary
This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
CollaboratorsCalithera Biosciences, Inc
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartAug 2017
Primary CompletionJul 2021
Study CompletionApr 2024
TodayJul 2026
First PostedMar 31, 2017
Enrollment StartAug 1, 2017
Primary CompletionJul 20, 2021
Study CompletionApr 24, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 9.3 years ago
Interventions
TAK-228drug
TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth